Daewon Pharm (003220.KS)
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.
Company Info
Highlights
₩298.35B
₩597.69B
₩281.06B
₩12,370.00 - ₩20,262.37
₩19,000.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Daewon Pharm (003220.KS) returned -2.32% year-to-date (YTD) and -2.13% over the past 12 months. Over the past 10 years, 003220.KS returned -1.29% annually, underperforming the S&P 500 benchmark at 10.85%.
003220.KS
-2.32%
0.94%
-1.66%
-2.13%
-4.93%
1.29%
-1.29%
^GSPC (Benchmark)
0.51%
5.49%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 003220.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 2.60% | -3.90% | -4.13% | 2.38% | 0.94% | -2.32% | |||||||
| 2024 | -6.45% | 1.30% | 0.40% | 0.40% | -2.87% | -3.03% | 12.85% | -4.84% | -3.11% | -2.11% | 0.77% | 0.68% | -7.04% |
| 2023 | -10.29% | -9.27% | -5.70% | 2.64% | -2.51% | -1.18% | 7.59% | 12.34% | -5.17% | -4.97% | 2.39% | 0.62% | -14.84% |
| 2022 | -12.91% | 28.97% | -0.86% | 1.11% | -5.49% | -9.59% | 13.83% | -7.34% | -7.32% | 10.86% | 5.64% | 7.36% | 18.22% |
| 2021 | -10.05% | 0.19% | -3.60% | 4.98% | -5.04% | 3.44% | -4.53% | 31.65% | -11.06% | -14.05% | -6.92% | 13.88% | -8.78% |
| 2020 | -8.38% | -9.02% | 1.79% | 3.51% | 3.73% | 12.42% | 23.26% | 0.94% | -5.14% | -12.32% | 8.15% | 1.62% | 16.47% |
| 2019 | 5.88% | -0.01% | -1.20% | 7.62% | -9.35% | -1.25% | -6.96% | -0.68% | 4.45% | 2.62% | 8.31% | 3.66% | 12.06% |
| 2018 | 5.87% | 9.42% | -12.98% | -2.20% | -2.75% | 2.83% | -3.75% | 1.82% | 1.53% | -18.84% | 3.41% | -1.65% | -19.04% |
| 2017 | 3.32% | 5.80% | -1.92% | 7.11% | -1.14% | -9.49% | -3.84% | 3.46% | -8.23% | -0.00% | 11.76% | 8.10% | 13.33% |
| 2016 | 5.67% | 13.49% | -3.16% | 1.51% | 1.73% | -4.38% | 13.49% | -16.59% | 1.08% | -9.31% | 8.50% | 7.36% | 15.91% |
| 2015 | 16.44% | 6.76% | 9.34% | -3.70% | 24.73% | 18.72% | -10.95% | -1.87% | -9.55% | -2.35% | -18.99% | 6.04% | 28.50% |
| 2014 | 25.60% | -3.20% | -5.79% | 7.89% | -9.76% | 0.45% | 1.35% | -1.33% | 21.97% | 21.69% | -9.67% | -1.33% | 48.21% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 003220.KS is 40, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Daewon Pharm (003220.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Daewon Pharm provided a 2.16% dividend yield over the last twelve months, with an annual payout of ₩300.00 per share.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | ₩300.00 | ₩300.00 | ₩300.00 | ₩350.00 | ₩194.17 | ₩147.94 | ₩233.40 | ₩226.61 | ₩215.82 | ₩209.53 | ₩156.48 | ₩111.77 |
Dividend yield | 2.16% | 2.11% | 1.92% | 1.87% | 1.20% | 0.82% | 1.50% | 1.61% | 1.22% | 1.33% | 1.13% | 1.03% |
Monthly Dividends
The table displays the monthly dividend distributions for Daewon Pharm. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | |||||||
| 2024 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩300.00 | ₩300.00 |
| 2023 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩300.00 | ₩300.00 |
| 2022 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩350.00 | ₩350.00 |
| 2021 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩194.17 | ₩194.17 |
| 2020 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩147.94 | ₩147.94 |
| 2019 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩233.40 | ₩233.40 |
| 2018 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩226.61 | ₩226.61 |
| 2017 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩215.82 | ₩215.82 |
| 2016 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩209.53 | ₩209.53 |
| 2015 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩156.48 | ₩156.48 |
| 2014 | ₩111.77 | ₩111.77 |
Dividend Yield & Payout
Dividend Yield
Daewon Pharm has a dividend yield of 2.16%, which is quite average when compared to the overall market.
Payout Ratio
Daewon Pharm has a payout ratio of 62.78%, which is quite average when compared to the overall market. This suggests that Daewon Pharm strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Daewon Pharm. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Daewon Pharm was 69.29%, occurring on Oct 27, 2008. Recovery took 401 trading sessions.
The current Daewon Pharm drawdown is 39.58%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -69.29% | Jun 4, 2007 | 337 | Oct 27, 2008 | 401 | Jun 1, 2010 | 738 |
| -68.33% | Mar 15, 2000 | 98 | Aug 8, 2000 | 362 | Feb 1, 2002 | 460 |
| -58.94% | Jun 24, 2002 | 265 | Jul 22, 2003 | 385 | Feb 28, 2005 | 650 |
| -56.82% | Jul 7, 2015 | 1157 | Mar 23, 2020 | 84 | Jul 23, 2020 | 1241 |
| -49.56% | Jun 16, 2005 | 246 | Jun 8, 2006 | 218 | Apr 24, 2007 | 464 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Daewon Pharm over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Daewon Pharm, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -119.5%.
Valuation
The Valuation section provides an overview of how Daewon Pharm is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 003220.KS compared to other companies in the Drug Manufacturers - Specialty & Generic industry. 003220.KS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 003220.KS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 003220.KS has a P/S ratio of 0.5. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 003220.KS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 003220.KS has a P/B value of 1.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |